* The remainder
of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover
page.
The information
required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the Notes).
|
CUSIP No. 931427108
|
13D
|
(Page 2 of 13 Pages)
|
|
1
|
Name of Reporting Person
Alliance Santé Participations S.A.
|
|
2
|
Check the Appropriate Box if a Member of a Group
(see instructions)
|
(a) ¨
(b) x
|
|
3
|
SEC Use Only
|
|
4
|
Source
of Funds (see instructions)
AF, WC
|
|
5
|
Check Box if Disclosure of Legal Proceedings is Required
Pursuant to Item 2(d) or 2(e)
|
¨
|
|
6
|
Citizenship or Place of Organization
Luxembourg
|
|
Number of Shares
Beneficially Owned By
Each Reporting
Person With
|
7
|
Sole Voting Power
144,788,821
|
|
8
|
Shared Voting Power
0
|
|
9
|
Sole Dispositive Power
144,788,821
|
|
10
|
Shared Dispositive Power
0
|
|
11
|
Aggregate Amount Beneficially Owned by Each Reporting Person
144,788,821
|
|
12
|
Check Box if the Aggregate Amount in Row (11) Excludes
Certain Shares (see instructions)
|
¨
|
|
13
|
Percent of Class Represented by Amount in Row (11)
16.7 % *
|
|
14
|
Type
of Reporting Person (see instructions)
CO
|
|
|
*
|
This calculation is based on 866,534,089 shares of Common Stock, par value $0.01 per share, outstanding
as of June 30, 2020, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended May 31, 2020
filed with the Securities and Exchange Commission on July 9, 2020.
|
|
CUSIP No. 931427108
|
13D
|
(Page 3 of 13 Pages)
|
|
1
|
Name of Reporting Person
NewCIP II S.à r.l.
|
|
2
|
Check the Appropriate Box if a Member of a Group
(see instructions)
|
(a) ¨
(b) x
|
|
3
|
SEC Use Only
|
|
4
|
Source
of Funds (see instructions)
AF
|
|
5
|
Check Box if Disclosure of Legal Proceedings is Required
Pursuant to Item 2(d) or 2(e)
|
¨
|
|
6
|
Citizenship or Place of Organization
Luxembourg
|
|
Number of Shares
Beneficially Owned By
Each Reporting
Person With
|
7
|
Sole Voting Power
144,788,821
|
|
8
|
Shared Voting Power
0
|
|
9
|
Sole Dispositive Power
144,788,821
|
|
10
|
Shared Dispositive Power
0
|
|
11
|
Aggregate Amount Beneficially Owned by Each Reporting Person
144,788,821
|
|
12
|
Check Box if the Aggregate Amount in Row (11) Excludes
Certain Shares (see instructions)
|
¨
|
|
13
|
Percent of Class Represented by Amount in Row (11)
16.7 % *
|
|
14
|
Type
of Reporting Person (see instructions)
CO
|
|
|
*
|
This calculation is based on 866,534,089 shares of Common Stock, par value $0.01 per share, outstanding
as of June 30, 2020, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended May 31, 2020
filed with the Securities and Exchange Commission on July 9, 2020.
|
|
CUSIP No. 931427108
|
13D
|
(Page 4 of 13 Pages)
|
|
1
|
Name of Reporting Person
Stefano Pessina
|
|
2
|
Check the Appropriate Box if a Member of a Group
(see instructions)
|
(a) ¨
(b) x
|
|
3
|
SEC Use Only
|
|
4
|
Source
of Funds (see instructions)
AF, PF
|
|
5
|
Check Box if Disclosure of Legal Proceedings is Required
Pursuant to Item 2(d) or 2(e)
|
¨
|
|
6
|
Citizenship or Place of Organization
Monaco
|
|
Number of Shares
Beneficially Owned By
Each Reporting
Person With
|
7
|
Sole Voting Power
146,113,290
|
|
8
|
Shared Voting Power
0
|
|
9
|
Sole Dispositive Power
146,113,290
|
|
10
|
Shared Dispositive Power
0
|
|
11
|
Aggregate Amount Beneficially Owned by Each Reporting Person
146,113,290
|
|
12
|
Check Box if the Aggregate Amount in Row (11) Excludes
Certain Shares (see instructions)
|
¨
|
|
13
|
Percent of Class Represented by Amount in Row (11)
16.9 % *
|
|
14
|
Type
of Reporting Person (see instructions)
IN
|
|
|
*
|
This calculation is based on 866,534,089 shares of Common Stock, par value $0.01 per share, outstanding
as of June 30, 2020, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended May 31, 2020
filed with the Securities and Exchange Commission on July 9, 2020.
|
Explanatory Note
This
Amendment No. 8 to Schedule 13D (this “Amendment No. 8”) is being filed by the Reporting Persons (as defined
below) and relates to the shares of common stock, par value $0.01 per share (the “Common Stock”), of Walgreens
Boots Alliance, Inc., a Delaware corporation (the “Issuer”). This Amendment No. 8 amends and
supplements the Schedule 13D filed by the Reporting Persons with the United States Securities and Exchange Commission (the “SEC”)
on December 31, 2014, as amended by Amendment No. 1 to Schedule 13D filed by the Reporting Persons with the SEC on January
20, 2015, by Amendment No. 2 to Schedule 13D filed by the Reporting Persons with the SEC on December 31, 2015, by Amendment No. 3
to Schedule 13D filed by the Reporting Persons with the SEC on November 4, 2016, by Amendment No. 4 to Schedule 13D filed
by the Reporting Persons with the SEC on January 17, 2018, by Amendment No. 5 to Schedule 13D filed by the Reporting Persons
with the SEC on July 17, 2018, by Amendment No. 6 to Schedule 13D filed by the Reporting Persons with the SEC on November
5, 2019, and by Amendment No. 7 to Schedule 13D filed by the Reporting Persons with the SEC on December 17, 2019 (as so amended,
the “Existing Schedule 13D”).
Capitalized terms
used in this Amendment No. 8 but not otherwise defined herein shall have the meanings ascribed to them in the Existing Schedule
13D. Except as specifically amended hereby, items in the Existing Schedule 13D remain unmodified.
|
|
Item 4.
|
Purpose of Transaction
|
Item 4 of the Existing Schedule 13D is
hereby amended and restated in its entirety to read as follows:
The information
set forth under Items 3 and 6 is hereby incorporated by reference.
The Reporting
Persons currently intend to hold the shares of Common Stock, held of record by ASP and Pessina, for the long-term. However, the
Reporting Persons will review on an ongoing and continuing basis their investment in the Issuer. Depending upon the factors discussed
below, the Reporting Persons (subject to applicable law, the contractual restrictions described herein and compliance with the
Issuer’s securities trading policies and procedures binding on Pessina) may acquire additional shares of Common Stock or
other securities of the Issuer or may sell shares of Common Stock or other securities of the Issuer. Further, subject
to applicable law, the contractual restrictions described herein and compliance with the Issuer’s securities trading policies
and procedures binding on Pessina, the Reporting Persons may enter into derivative transactions or alternative structures with
respect to the shares of Common Stock or the economic or voting rights attached thereto. Subject to applicable law,
the contractual restrictions described herein and compliance with the Issuer’s securities trading policies and procedures
binding on Pessina, any open market or privately negotiated purchases, sales, distributions or other transactions may be made at
any time without additional prior notice. Any alternative that the Reporting Persons may pursue will depend upon a variety of factors,
including, without limitation, current and anticipated future trading prices of the shares of Common Stock or other securities
of the Issuer, the financial condition, results of operations and prospects of the Issuer and general economic, financial market
and industry conditions, other investment and business opportunities available to the Reporting Persons, general stock market and
economic conditions, tax considerations and other factors.
In his
capacity as the Chief Executive Officer of the Issuer, Pessina takes an active role in working with the other senior members of
the Issuer’s management on operational, financial and strategic initiatives. Accordingly, in the course of his duties, Pessina
may consider matters related to items (a) through (j) of Schedule 13D and, subject to applicable law, fiduciary duties and contractual
restrictions, may formulate a plan with respect to such matters, and, from time to time, may hold discussions with or make formal
proposals to management or the Board of Directors of the Issuer, other stockholders of the Issuer or other third parties regarding
such matters. As a director, Pessina may also be asked to vote on or further discuss such matters.
On July
27, 2020, the Issuer announced that:
|
|
·
|
Pessina has informed the Issuer of his decision to step down from the role of Chief Executive Officer
of the Issuer and, as a result, the Issuer will commence a search for a successor to Pessina as Chief Executive Officer, with Pessina
continuing to serve as Executive Vice Chairman and Chief Executive Officer until a new Chief Executive Officer takes office;
|
|
|
·
|
James A. Skinner, the Issuer’s Executive Chairman of the Board, also has informed the Issuer
of his decision to step down from that role when a new Chief Executive Officer takes office, while remaining on the Board to provide
continuity to the Board during the management transition; and
|
|
|
·
|
when the new Chief Executive Officer takes office, the Board will appoint Pessina on an annual
basis (subject to applicable law, including fiduciary duties), as Executive Chairman, provided that Pessina is a member of the
Board of the Company at the time (and upon his initial appointment as Executive Chairman, Pessina would resign as Executive Vice
Chairman).
|
The Issuer
and Pessina have entered into a letter agreement with respect to certain of these matters and the foregoing description is qualified
in its entirety by reference to the full text of the letter agreement, which is attached hereto as Exhibit N.
Except
as set forth in this Statement, none of the Reporting Persons or, to the knowledge of the Reporting Persons, any of the persons
listed in Annex A hereto, has any current intention, plan or proposal that relate to or would result in any of the transactions
involving the Issuer described in subparagraphs (a) through (j) of Item 4 of Schedule 13D; however, the Reporting Persons or persons
listed in Annex A hereto may from time to time consider pursuing or proposing any or all of the transactions described in subparagraphs
(a) through (j) of Item 4 of Schedule 13D.
|
|
Item 5.
|
Interest in Securities of the Issuer.
|
Item 5 of the Existing Schedule 13D is
hereby amended and restated in its entirety to read as follows:
The
ownership percentages set forth below are based on 866,534,089 shares of Common Stock, par value $0.01 per share, outstanding
as of June 30, 2020, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended May 31, 2020
filed with the Securities and Exchange Commission on July 9, 2020.
|
|
(a)
|
The Reporting Persons beneficially own an aggregate of 146,113,290 shares of Common Stock, which
represent, in the aggregate, approximately, 16.9% of the outstanding shares of Common Stock. Of these: (i) 144,788,821 shares
of Common Stock are held directly and of record by ASP; (ii) 182,707 shares of Common Stock are held directly and of record
by Pessina; and (iii) 1,141,762 shares of Common Stock are subject to employee stock options granted to Pessina that are exercisable
as of, or within 60 days after, the date of this Amendment No. 8. All such stock options are “out-of-the-money”
having exercise prices in excess of US$ 40.51, being the closing price on July 24, 2020, the trading day immediately preceding
the date of this Amendment No. 8. The number does not include 78,700 shares of Common Stock underlying restricted stock units awarded
to Pessina (being 76,570 shares underlying restricted stock units awarded to Pessina on November 1, 2019 and 2,130 shares underlying
restricted stock units issued in lieu of dividends on outstanding restricted stock units). The shares of Common Stock underlying
these restricted stock units vest with respect to 25,498 shares (plus any shares underlying restricted stock units issued in lieu
of dividends on such shares) on November 1, 2020, with respect to 25,498 shares (plus any shares underlying restricted stock units
issued in lieu of dividends on such shares) on November 1, 2021, and with respect to 25,574 shares (plus any shares underlying
restricted stock units issued in lieu of dividends on such shares) on November 1, 2022, subject to acceleration or forfeiture in
certain circumstances in accordance with the terms and conditions of their award.
|
The number of shares of Common
Stock beneficially owned by the persons listed in Annex A is set forth therein and is incorporated herein by reference.
|
|
(b)
|
ASP has the sole power to vote and the sole power to dispose of the 144,788,821 shares of Common
Stock held directly and of record by ASP, which shares represent approximately 16.7% of the outstanding shares of Common Stock.
NewCIP II is the sole shareholder of ASP and Pessina holds 100% voting control over NewCIP II; accordingly each of NewCIP II
and Pessina may be deemed to be the beneficial owner of the 144,788,821 shares of Common Stock held directly and of record by ASP.
In addition, Pessina has the sole power to vote and the sole power to dispose of the 182,707 shares of Common Stock that he holds
directly and of record, which shares represent approximately 0.02% of the outstanding shares of Common Stock. Finally, on their
exercise, Pessina would have the sole power to vote and the sole power to dispose of the 1,141,762 shares of Common Stock that
are subject to the employee stock options he holds that are exercisable as of, or within 60 days after, the date of this Amendment
No. 8, which shares represent approximately 0.1% of the outstanding shares of Common Stock.
|
The information with respect
to the voting and dispositive power of the shares of Common Stock beneficially owned by the persons listed in Annex A is set forth
therein and is incorporated herein by reference.
|
|
(c)
|
Other than as described elsewhere in this Schedule 13D
(including the information in Item 3 which is incorporated herein by reference), the Reporting Persons and, to the knowledge of
the Reporting Persons, the persons listed in Annex A hereto have effected no transactions in shares of Common Stock during the
last sixty (60) days.
|
|
|
(d)
|
Other than the Reporting Persons and the persons listed in Annex A hereto, no other person is known
to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the Reporting
Persons’ securities or, to the knowledge of the Reporting Persons, the securities of the persons listed in Annex A hereto,
respectively.
|
|
|
Item 7.
|
Material to be Filed as Exhibits.
|
Item 7 of the Existing Schedule 13D is
hereby amended and supplemented by adding the following at the end thereof:
|
|
Exhibit N.
|
Letter Agreement, dated July 23, 2020, by and between
Stefano Pessina and Walgreens Boots Alliance, Inc. (incorporated herein by reference to Exhibit 10.1 of the Form 8-K filed by
the Issuer on July 27, 2020 (file number 001-36759)).
|
SIGNATURE
After reasonable
inquiry and to the best of the undersigned’s knowledge and belief, the undersigned certifies that the information set forth
in this statement is true, complete and correct.
Date: July 27, 2020
|
|
Alliance Sante Participations S.A.
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Stefano Pessina
|
|
|
|
Name: Stefano Pessina
|
|
|
|
Title: Administrateur (Director)
|
|
|
|
|
|
|
|
|
|
|
NewCIP II S.à r.l.
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Stefano Pessina
|
|
|
|
Name: Stefano Pessina
|
|
|
|
Title: Manager
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Stefano Pessina
|
|
|
|
Stefano Pessina
|
ANNEX A
Alliance Sante Participations S.A. and NewCIP II S.A r.l.
The directors of Alliance Santé
Participations S.A. are the same individuals as the managers of NewCIP II S.à r.l.
Directors/Managers
Stefano Pessina
Business Address: 24 Boulevard du Ténao, Monte Carlo,
98000 Monaco.
Citizenship: Monaco.
Present Principal Occupation: Chief Executive Officer, Walgreens
Boots Alliance, Inc.
Beneficial Ownership of Issuer: See cover page for Stefano Pessina
and Item 5 of the Statement.
Ornella Barra
Business Address: 24 Boulevard du Ténao, Monte Carlo,
98000 Monaco.
Citizenship: Monaco.
Present Principal Occupation: Co-Chief Operating Officer, Walgreens
Boots Alliance, Inc.
Beneficial Ownership of Issuer: 2,148,010 shares of Common Stock;
approximately 0.24% of outstanding shares.(1)(2)(3)
Jean-Paul Goerens
Personal Address: 6, Lacets Saint Léon, Monte
Carlo, 98000 Monaco.
Citizenship: Luxembourg.
Present Principal Occupation: Self-employed lawyer.
Beneficial Ownership of Issuer: 4,000 shares of Common Stock;
less than 0.01% of outstanding shares.(1)(4)
Simone Retter
Business Address: 14, avenue du X Septembre, L-2550
Luxembourg, Grand Duchy of Luxembourg.
Citizenship: Luxembourg.
Present Principal Occupation: Self-employed lawyer.
Beneficial Ownership of Issuer: 1,100 shares of Common Stock;
less than 0.01% of outstanding shares.(1)(4)
Other than the foregoing, neither Alliance Santé Participations
S.A. nor NewCIP II S.à r.l. has any other directors, managers or executive officers.
Notes:
|
|
(1)
|
Ownership percentages are based on 866,534,089 shares of Common Stock, par value $0.01 per share,
outstanding as of June 30, 2020, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended
May 31, 2020 filed with the Securities and Exchange Commission on July 9, 2020.
|
|
|
·
|
1,718,000 shares of Common Stock held directly and of record by OLB Holdings Ltd., an exempted
limited company incorporated in the Cayman Islands (“OLB”). OLB has sole voting and dispositive power
with respect to the shares of Common Stock it holds. Ornella Barra owns 100% of the share capital and voting power of
OLB and may be deemed to be the beneficial owner of the 1,718,000 shares of Common Stock held by OLB.
|
|
|
·
|
52,739 shares of Common Stock held directly and of record by Ornella Barra, with respect to which
she has sole voting and dispositive power.
|
|
|
·
|
377,271 shares of Common Stock subject to employee stock options granted to Ornella Barra that
are exercisable as of, or within 60 days after, the date of this Amendment No. 8. All such stock options are “out-of-the-money”
having exercise prices in excess of US$ 40.51, being the closing price on July 24, 2020, the trading day immediately preceding
the date of this Amendment No. 8.
|
|
|
(3)
|
The number does not include:
|
|
|
·
|
22,134 shares of Common Stock underlying restricted stock units awarded to Ornella Barra (being
21,535 shares underlying restricted stock units awarded to Ornella Barra on November 1, 2019 and 599 shares underlying restricted
stock units issued in lieu of dividends on outstanding restricted stock units). The shares of Common Stock underlying these restricted
stock units vest with respect to 7,171 shares (plus any shares underlying restricted stock units issued in lieu of dividends on
such shares) on November 1, 2020, with respect to 7,171 shares (plus any shares underlying restricted stock units issued in lieu
of dividends on such shares) on November 1, 2021, and with respect to 7,193 shares (plus any shares underlying restricted stock
units issued in lieu of dividends on such shares) on November 1, 2022, subject to acceleration or forfeiture in certain circumstances
in accordance with the terms and conditions of their award.
|
|
|
·
|
26,202 shares of Common Stock underlying restricted stock units awarded to Ornella Barra (being
25,681 shares underlying restricted stock units awarded to Ornella Barra on December 10, 2019 and 521 shares underlying restricted
stock units issued in lieu of dividends on outstanding restricted stock units). The shares underlying these restricted stock units
vest with respect to 12,840 shares (plus any shares underlying restricted stock units issued in lieu of dividends on such shares)
on September 1, 2020 and with respect to 12,841 shares (plus any shares underlying restricted stock units issued in lieu of dividends
on such shares) on September 1, 2021, subject to acceleration or forfeiture in certain circumstances in accordance with the terms
and conditions of their award.
|
|
|
(4)
|
Each of Mr. Goerens and Ms. Retter has sole voting and dispositive power with respect to the shares
of Common Stock he or she holds.
|
EXHIBIT INDEX
|
|
Exhibit A.
|
Joint Filing Agreement, dated December 31, 2014, by and
among, AB Acquisitions Holdings Limited, Alliance Santé Participations S.A., NEWCIP S.A. and Stefano Pessina. *
|
|
|
Exhibit B
|
Purchase and Option Agreement, dated as of June 18, 2012,
by and among Alliance Boots GmbH, AB Acquisitions Holdings Limited, and Walgreen Co. (incorporated herein by reference to Exhibit
2.1 of the Form 8-K filed by the Original Issuer on June 19, 2012 (file number 001-00604))
|
|
|
Exhibit C
|
Shareholders Agreement, dated as of August 2, 2012, by
and among Walgreen Co., Stefano Pessina, KKR Sprint (Europe II) Limited, KKR Sprint (2006) Limited and KKR Sprint (KPE) Limited,
Alliance Santé Participations S.A., each of the persons becoming a party thereto and Kohlberg Kravis Roberts & Co.
L.P. (incorporated herein by reference to Exhibit 4.1 of the Form 8-K filed by the Original Issuer on August 6, 2012 (file number
001-00604)).
|
|
|
Exhibit D
|
Amendment No. 1, dated August 5, 2014, to the Purchase
and Option Agreement and Walgreen Co. Shareholders Agreement, by and among Walgreen Co., Alliance Boots GmbH, AB Acquisitions
Holdings Limited, Walgreen Scotland Investments LP, KKR Sprint (European II) Limited, KKR Sprint (2006) Limited and KKR Sprint
(KPE) Limited, Alliance Santé Participations S.A., Stefano Pessina and Kohlberg Kravis Roberts & Co. L.P. (incorporated
herein by reference to Exhibit 2.1 of the Form 8-K filed by the Original Issuer on August 6, 2014 (file number 001-00604)).
|
|
|
Exhibit E
|
Amendment No. 2, dated December 31, 2014, to the Purchase
and Option Agreement and Walgreen Co. Shareholders Agreement, as Amended by Amendment No. 1, dated as of August 5, 2014, by and
among Walgreen Co., Alliance Boots GmbH, AB Acquisitions Holdings Limited, Ontario Holdings WBS Limited, KKR Sprint (European
II) Limited, KKR Sprint (2006) Limited and KKR Sprint (KPE) Limited, Alliance Santé Participations S.A., Stefano Pessina
and Kohlberg Kravis Roberts & Co. L.P. *
|
|
|
Exhibit F
|
Notification Letter, dated December 31, 2014, from Walgreens
to Alliance Boots GmbH, AB Acquisitions Holdings Limited, KKR Sprint (European II) Limited, KKR Sprint (2006) Limited, KKR Sprint
(KPE) Limited, Kohlberg Kravis Roberts & Co. L.P., Alliance Santé Participations S.A. and Stefano Pessina. *
|
|
|
Exhibit G
|
First Amendment to Joint Filing Agreement, dated as of
November 4, 2016, by and among Sprint Acquisitions Holdings Limited (formerly known as AB Acquisitions Holdings Limited), Alliance
Santé Participations S.A., NEWCIP S.A., and Stefano Pessina. **
|
|
|
Exhibit H
|
Stock Purchase and Sale Agreement, dated October 31,
2016, by and among KKR Sprint (2006) Limited, KKR Sprint (European II) Limited, KKR Sprint (KPE) Limited, KKR European Co-Invest
Fund I, L.P., KKR Reference Fund Investments L.P., KKR Associates Reserve LLC, KKR Associates 2006 (Overseas), Limited Partnership
and Sprint Co-Invest 2 L.P., as sellers, and Alliance Santé Participations S.A., as purchaser. **
|
|
|
Exhibit I
|
Assignment Agreement, dated January 15, 2018, by and
between Stefano Pessina and Alliance Santé Participations S.A. ***
|
|
|
Exhibit J
|
Loan Agreement, dated January 15, 2018, by and between
Stefano Pessina, as lender, and Alliance Santé Participations S.A., as borrower. ***
|
|
|
Exhibit K
|
Share Purchase Agreement, dated July 16, 2018, by and
between Ornella Barra and Alliance Santé Participations S.A. ****
|
|
|
Exhibit L
|
Loan Agreement, dated July 16, 2018, by and between Alliance
Finance Ltd., as lender, and Alliance Santé Participations S.A., as borrower. ****
|
|
|
Exhibit M.
|
Joint Filing Agreement, dated December 17, 2019, by and
among, Alliance Santé Participations S.A., NEWCIP S.A. (in liquidation), NewCIP II S.à r.l. and Stefano Pessina. *****
|
|
|
Exhibit N.
|
Letter Agreement, dated July 23, 2020, by and between
Stefano Pessina and Walgreens Boots Alliance, Inc. (incorporated herein by reference to Exhibit 10.1 of the Form 8-K filed by
the Issuer on July 27, 2020 (file number 001-36759)).
|
|
*
|
Filed with original Schedule 13D, dated December 31, 2014.
|
|
**
|
Filed with Amendment No.3 to Schedule 13D, dated November 4, 2016.
|
|
***
|
Filed with Amendment No.4 to Schedule 13D, dated January 17, 2018.
|
|
****
|
Filed with Amendment No.5 to Schedule 13D, dated July 17, 2018.
|
|
*****
|
Filed with Amendment No.7 to Schedule 13D, dated December 17, 2019.
|